(Post-pandemic Era)-Global Age-related Macular Degeneration Market (Sales, Revenue, Price, Gross Profit and Competitors Analysis of Major Market) from 2016-2027
- Report Code : XYZ2438146
- Published On: Apr, 2021
- Category : Medical Devices
- Pages : 114
-
As the world continues to deal with COVID-19, economies are moving into recession, under multiple adverse factors, the GDP of European and American countries in the second quarter suffered a historical contraction. At an annualized rate, the US GDP fell by 32.9% month on month, while the overall GDP of the euro zone fell by 12.1%.
Moreover, the economic prospects of Europe and the United States in the third quarter under the epidemic situation are hardly optimistic. The resumption of work and production not only brought economic data back, but also triggered a rebound in the epidemic situation. At present, the United States is still the 'epicenter' of the global epidemic. The total number of confirmed cases has exceeded 4.8 million, and the epidemic situation in some European countries has also rebounded. Affected by this, more than 20 states in the United States have announced the suspension or withdrawal of part of the economic restart plan. Britain and Italy have also decided to extend the state of emergency. The rebound of the epidemic situation has posed considerable risks to the economic prospects of Europe and the United States.
In the second quarter of this year, US GDP shrank by 9.5% on a month on month basis, or 32.9% at an annual rate, the largest decline since the 1940s. Data show that the sharp decline in personal consumption is the main drag on the U.S. GDP growth in the second quarter.
Compared with the United States, Europe's economic contraction in the second quarter was smaller, but it was also the lowest on record, with Germany and France contracting more than 10%. According to the data released by the Federal Bureau of statistics, Germany's GDP fell by 10.1% in the second quarter after adjusting for prices, seasons and working days, the largest decline since the quarterly economic data were available in 1970.
Thanks to the effective control and policy support of the new epidemic, China's economy rebounded sharply in the second quarter. The growth rate of manufacturing industry, which accounted for about 28% of GDP, rebounded sharply to 4.4% from the negative value in the first quarter. Chinese original equipment manufacturers (OEMs) and suppliers are ramping up production. And there are increased investments in digital footprints in manufacturing. OEMs in other parts of the world are offering incentives to drive sales. Research published a report for global Age-related Macular Degeneration market in this environment.
In terms of revenue, this research report indicated that the global Age-related Macular Degeneration market was valued at USD XXX million in 2020, and it is expected to reach a value of USD XXX million by 2027, at a CAGR of XX % over the forecast period 2021-2027. Correspondingly, the forecast analysis of Age-related Macular Degeneration industry comprises of China, USA, Japan, India, Korea and South America, with the production and revenue data in each of the sub-segments.
The Bayer HealthCare aims at producing XX K Units Age-related Macular Degeneration in 2020, with XX % production to take place in global market, F. Hoffmann-La Roche accounts for a volume share of XX %.
Regional Segmentation (Value; Revenue, USD Million, 2026-2027) of Age-related Macular Degeneration Market Include by
China
EU
USA
Japan
India
Southeast Asia
South America
Competitive Analysis; Who are the Major Players in Age-related Macular Degeneration Market
Bayer HealthCare
F. Hoffmann-La Roche
Novartis
Regeneron Pharmaceuticals
Alcon
Allergan
Avalanche
Bausch+Lomb
Gilead Sciences
Iconic Therapeutics
Neurotech Pharmaceuticals
Ohr Pharmaceutical
Major Type of Age-related Macular Degeneration Covered in Research report:
Wet AMD
Dry AMD
Application Segments Covered in Research Market
Drugstore
Hospital
Others
For any other requirements, please feel free to contact us and we will provide you customized report.
-
With tables and figures helping analyze worldwide (Post pandemic Era) Global Age related Macular Degeneration market, this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.
Global Age-related Macular Degeneration Market Analysis 2021, With Top Companies, Production, Revenue, Consumption, Price and Growth Rate
1 Market Scope1.1 Product Details and Introduction
1.1.1 Wet AMD -Product Introduction and Major Manufacturers
1.1.2 Dry AMD -Product Introduction and Major Manufacturers1.2 Market Snapshot
1.2.1 Major Companies Overview
1.2.2 Market Concentration
1.2.3 Six-Year Compound Annual Growth Rate (CAGR)
2 Global Age-related Macular Degeneration Market Assessment, by Segmentation2.1 Type Breakdown Estimates & Forecast, Sales Volume (2026-2027)
2.2 Type Breakdown Estimates & Forecast, Sales Value (2026-2027)
2.3 Application Breakdown Estimates & Forecast, by Application (2026-2027)
3 Regional Market Analysis3.1 China Age-related Macular Degeneration Market
3.1.1 Top Companies leading Age-related Macular Degeneration Development in China (2016-2021)
3.1.2 Sales Value of Major Company in China Market (2016-2021)
3.1.3 China Age-related Macular Degeneration Price (USD/Unit), by Type (2019-2020)
3.1.4 Sales in China Market, by Type (2026-2027)3.2 EU Age-related Macular Degeneration Market
3.2.1 Top Companies leading Age-related Macular Degeneration Development in EU (2016-2021)
3.2.2 Sales Value of Major Company in EU Market (2016-2021)
3.2.3 EU Age-related Macular Degeneration Price (USD/Unit), by Type (2019-2020)
3.2.4 Sales in EU Market, by Type (2026-2027)3.3 USA Age-related Macular Degeneration Market
3.3.1 Top Companies leading Age-related Macular Degeneration Development in USA (2016-2021)
3.3.2 Sales Value of Major Company in USA Market (2016-2021)
3.3.3 USA Age-related Macular Degeneration Price (USD/Unit), by Type (2019-2020)
3.3.4 Sales in USA Market, by Type (2026-2027)3.4 Japan Age-related Macular Degeneration Market
3.4.1 Top Companies leading Age-related Macular Degeneration Development in Japan (2016-2021)
3.4.2 Sales Value of Major Company in Japan Market (2016-2021)
3.4.3 Japan Age-related Macular Degeneration Price (USD/Unit), by Type (2019-2020)
3.4.4 Sales in Japan Market, by Type (2026-2027)3.5 India Age-related Macular Degeneration Market
3.5.1 Top Companies leading Age-related Macular Degeneration Development in India (2016-2021)
3.5.2 Sales Value of Major Company in India Market (2016-2021)
3.5.3 India Age-related Macular Degeneration Price (USD/Unit), by Type (2019-2020)
3.5.4 Sales in India Market, by Type (2026-2027)3.6 Southeast Asia Age-related Macular Degeneration Market
3.6.1 Top Companies leading Age-related Macular Degeneration Development in Southeast Asia (2016-2021)
3.6.2 Sales Value of Major Company in Southeast Asia Market (2016-2021)
3.6.3 Southeast Asia Age-related Macular Degeneration Price (USD/Unit), by Type (2019-2020)
3.6.4 Sales in Southeast Asia Market, by Type (2026-2027)
3.7 South America Age-related Macular Degeneration Market
3.7.1 Top Companies leading Age-related Macular Degeneration Development in South America (2016-2021)
3.7.2 Sales Value of Major Company in South America Market (2016-2021)
3.7.3 South America Age-related Macular Degeneration Price (USD/Unit), by Type (2019-2020)
3.7.4 Sales in South America Market, by Type (2026-2027)
4 Value Chain (Impact of COVID-19)4.1 Age-related Macular Degeneration Value Chain Analysis
4.1.1 Upstream
4.1.2 Downstream4.2 COVID-19 Impact on Age-related Macular Degeneration Industry
4.2.1 Industrial Policy Issued Under the Epidemic Situation4.3 Cost-Under the Epidemic Situation
4.3.1 Cost of Raw Material4.4 Channel Analysis
4.4.1 Distribution Channel-Under the Epidemic Situation
4.4.2 Distributors
5 Regional Market Forecast (2021-2027)5.1 Global Age-related Macular Degeneration Sales and Growth Rate (2021-2027)
5.2 Global Age-related Macular Degeneration Sales Value and Growth Rate (2021-2027)
6 Age-related Macular Degeneration Competitive Analysis6.1 Bayer HealthCare
6.1.1 Bayer HealthCare Company Profiles
6.1.2 Bayer HealthCare Product Introduction
6.1.3 Bayer HealthCare Age-related Macular Degeneration Production, Revenue (2016-2021)
6.1.4 SWOT Analysis6.2 F. Hoffmann-La Roche
6.2.1 F. Hoffmann-La Roche Company Profiles
6.2.2 F. Hoffmann-La Roche Product Introduction
6.2.3 F. Hoffmann-La Roche Age-related Macular Degeneration Production, Revenue (2016-2021)
6.2.4 SWOT Analysis6.3 Novartis
6.3.1 Novartis Company Profiles
6.3.2 Novartis Product Introduction
6.3.3 Novartis Age-related Macular Degeneration Production, Revenue (2016-2021)
6.3.4 SWOT Analysis6.4 Regeneron Pharmaceuticals
6.4.1 Regeneron Pharmaceuticals Company Profiles
6.4.2 Regeneron Pharmaceuticals Product Introduction
6.4.3 Regeneron Pharmaceuticals Age-related Macular Degeneration Production, Revenue (2016-2021)
6.4.4 SWOT Analysis6.5 Alcon
6.5.1 Alcon Company Profiles
6.5.2 Alcon Product Introduction
6.5.3 Alcon Age-related Macular Degeneration Production, Revenue (2016-2021)
6.5.4 SWOT Analysis6.6 Allergan
6.6.1 Allergan Company Profiles
6.6.2 Allergan Product Introduction
6.6.3 Allergan Age-related Macular Degeneration Production, Revenue (2016-2021)
6.6.4 SWOT Analysis
6.7 Avalanche
6.7.1 Avalanche Company Profiles
6.7.2 Avalanche Product Introduction
6.7.3 Avalanche Age-related Macular Degeneration Production, Revenue (2016-2021)
6.7.4 SWOT Analysis
6.8 Bausch+Lomb
6.8.1 Bausch+Lomb Company Profiles
6.8.2 Bausch+Lomb Product Introduction
6.8.3 Bausch+Lomb Age-related Macular Degeneration Production, Revenue (2016-2021)
6.8.4 SWOT Analysis
6.9 Gilead Sciences
6.9.1 Gilead Sciences Company Profiles
6.9.2 Gilead Sciences Product Introduction
6.9.3 Gilead Sciences Age-related Macular Degeneration Production, Revenue (2016-2021)
6.9.4 SWOT Analysis6.10 Iconic Therapeutics
6.10.1 Iconic Therapeutics Company Profiles
6.10.2 Iconic Therapeutics Product Introduction
6.10.3 Iconic Therapeutics Age-related Macular Degeneration Production, Revenue (2016-2021)
6.10.4 SWOT Analysis
6.11 Neurotech Pharmaceuticals
6.12 Ohr Pharmaceutical
7 Conclusion
-
The (Post pandemic Era) Global Age related Macular Degeneration Market has been segregated into various crucial divisions including applications, types, and regions. Each market segment is intensively studied in the report contemplating its market acceptance, worthiness, demand, and growth prospects. The segmentation analysis will help the client to customize their marketing approach to have a better command of each segment and to identify the most prospective customer base.
Report Objectives / Segmentation Covered :
By Companies / players:
By Regions:
By Type:
By Application:
Frequently asked questions(FAQ's):
New players are entering the (Post pandemic Era) Global Age related Macular Degeneration Market, while established companies are changing their business models and strategies. This pattern is likely to continue for the foreseeable future.
Depending upon the type of applications, the (Post pandemic Era) Global Age related Macular Degeneration Market has been segmented into
In recent years, the (Post pandemic Era) Global Age related Macular Degeneration Market has grown at an incredible rate. From 2024 to 2029, the market is expected to grow at a CAGR of yy%.
Consumer behavior changes will reshape the entire decision-making process and companies in the (Post pandemic Era) Global Age related Macular Degeneration Industry will need to adapt quickly.
Companies in the (Post pandemic Era) Global Age related Macular Degeneration Industry are thoroughly researched and profiled in order to determine why certain trends will have a significant impact and how they will be factored into the (Post pandemic Era) Global Age related Macular Degeneration Market's trajectory and future outlook.
